Radiotheranostics Market Current Trends and Future Scope Analysis Report

Companies covered in this report are TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, Boston Scientific Corporation, Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, Theragnostics Ltd., NuView Life Sciences, Jubilant Pharma Limited, and Clarity Pharmaceuticals

Jersey City, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) — “Radiotheranostics Market” in terms of revenue was estimated to be worth $1.84 billion in 2023 and is poised to reach $4.36 billion by 2031, growing at a CAGR of 11.58% from 2024 to 2031 according to a new report by InsightAce Analytic.

Latest Drivers Restraint and Opportunities Market Snapshot:

Key factors influencing the global radiotheranostics market are:

  • Technological advancement
  • Increasing awareness
  • Increasing Cancer Rate

The following are the primary obstacles to the radiotheranostics ,arket ‘s expansion:

  • Restrictive Rules
  • Problems with Rollout Costs
  • Health data ethics and privacy concerns

Future expansion opportunities for the global radiotheranostics market include:  

  • Growing population
  • Beneficial Government Programs
  • Growth in treatment alternatives

Free PDF Report Brochure @

Market Analysis:

The worldwide radiotheranostics market is expected to be driven by the growing demand for precision medicine and the expanding use of nuclear medicine in the treatment of a wide range of chronic illnesses. Additionally, a growing need for biologically active radiotheranostics to target particular disorders and track the results of continuing treatment is driving positive changes in the global market.

List of Prominent Players in the Radiotheranostics Market:

  • Novartis AG
  • Bayer AG
  • Progenics Pharmaceuticals, Inc. ( Lantheus)
  • Telix Pharmaceuticals Limited.
  • ITM Radiopharma
  • Life Molecular Imaging.
  • RadioMedix
  • IsoTherapeutics Group, LLC
  • Q BioMed Inc.
  • Nordic Nanovector ASA

Radiotheranostics Market Report Scope:

Report Attribute Specifications
Market size value in 2023 USD 1.84 Bn
Revenue forecast in 2031 USD 4.36 Bn
Growth rate CAGR CAGR of 11.58% from 2024 to 2031
Quantitative units Representation of revenue in US$ Bn, and CAGR from 2024 to 2031
Historic Year 2019 to 2023
Forecast Year 2024-2031
Report coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments covered By Radioisotope, Source, Approach, Application, End-User
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Recent Developments:

  • In January 2024, Novartis reported data from the NETTER-2 Phase III trial. When administered as first-line therapy, the study indicated that a 72% reduction in the risk of disease progression or mortality was achieved with the combination of Lutathera oxo octreotide and long-acting release (LAR) octreotide, as compared to high-dose octreotide LAR alone1.
  • In January 2024, Telix developed an investigational positron emission tomography (PET) imaging agent called TLX250-CDx (89Zr-DFO-brentuximab) that is used to manage clear cell renal cell carcinoma (ccRCC), the most frequent and aggressive kind of kidney cancer.
  • In January 2024, ITM Isotope Technologies Munich SE (ITM) received the Radioactive Material Handling License (RAM License), according to the announcement made by the industry-leading radiopharmaceutical biotech firm. A novel medical radioisotope, lutetium-177, is used extensively in radiopharmaceutical therapy (RPT) to combat cancer. The RAM License and all other necessary regulatory clearances have been secured, and ITM is now operationally ready.

Curious about this latest version of the report? @

Radiotheranostics Market Dynamics:

Market Drivers: Increasing Cancer Rate

The healthcare industry is experiencing a surge in demand for radiotheranostics due to the increased incidence of cancer, which is fueling the rise of the market. Crucial to cancer management are diagnostic and therapeutic abilities, the ability to image cancer cells accurately, and the facilitation of focused therapy, which enhances treatment results and is another major growth-inducing factor. Further fueling the market’s expansion is radiopharmaceuticals’ ability to accurately diagnose cancer, which helps select the most appropriate treatment for individual patients. Radio theranostics also aids in monitoring therapy efficacy and illness progression, contributing to the market’s growth.

Challenges: Problems with Rollout Costs

The high price tag of radiopharmaceuticals and radiotherapeutic treatments could be a problem for families and doctors. More adoption and growth in the market can be achieved if we find solutions to the problems of these technologies’ cost-effectiveness and affordability. Reimbursement regulations and coverage for radiopharmaceuticals and radiotheranostics operations can be circumscribed in specific scenarios. The financial burden this places on individuals and healthcare providers could seriously limit the use of radiotheranostics.

North America is Expected to Grow with the Highest CAGR During the Forecast Period

The North America radiotheranostics Market is likely to register a significant revenue share and develop at a rapid CAGR in the near future. This is because of the rising need for therapeutic radiopharmaceuticals, the popularity of precision medicine, and the widespread use of advanced imaging technologies. The regional market is expected to be driven by rising national spending on precision medicine. Moreover, the sector in the region is being propelled even further by the existence of many market participants and the different strategic initiatives they have deployed.

Unlock Radiotheranostics Market GTM Strategy @

Segmentation of Radiotheranostics Market-

By Radioisotope-

  • Technetium-99
  • Gallium-68
  • Iodine-131
  • Iodine-123
  • 18F
  • Y-90
  • Lutetium (Lu) 177
  • Copper (Cu) 67
  • Copper (Cu) 64
  • Others

By Approach-

  • Targeted Therapeutic (Rx)
  • Targeted Diagnostic (DX)

By Application-

  • Oncology
    • Thyroid Cancer
    • Neuroendocrine Cancer
    • Hepatocellular Carcinoma
    • Multiple Myeloma
    • Lymphoma
    • Others
  • Non-Oncology
    • Joint Infections
    • Arthritis
    • Bone Pain
    • Others

By Source-

  • Nuclear Reactors
  • Cyclotrons

By End-users

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @

Subscribe Our Exclusive Newsletters @

CONTACT: Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 551 226 6109 Email: Site Visit:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy